Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 22, Issue 19, 2004, Pages 3852-3859

  Hotta, Katsuyuki ^a   Matsuo, Keitaro ^a   Ueoka, Hiroshi ^a   Kiura, Katsuyuki ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; NEW DRUG; PLATINUM; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; COMPARATIVE STUDY; LUNG TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 5444235920     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.109     Document Type: Article

References (25)

1. Stanley K, Stjernsward J: Lung cancer-A worldwide health problem. Chest 96:1S-5S, 1989
2. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995
3. Raby B, Pater J, Mackillop WJ: Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13:1904-1911, 1995
4. Muggia FM: Overview of carboplatin: Replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 16:7-13, 1989 (2 Suppl 5)
5. Bunn PA Jr: Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 20:23S-33S, 2002 (18 suppl)
6. Klastersky J, Sculier JP, Lacroix H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8:1556-1562, 1990
7. Jelic S, Mitrovic L, Radosavljevic D, et al: Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IMB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study. Lung Cancer 34:1-13, 2001
8. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
9. Zatloukal P, Petruzelka L, Zemanova M, et al: Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 41:321-331, 2003
10. Rosell R, Gatzemeier U, Betticher DC, et al: Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 13:1539-1549, 2002
11. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX326 Study Group. J Clin Oncol 21:3016-3024, 2003
12. Mazzanti P, Massacesi C, Rocchi MB, et al: Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41:81-89, 2003
13. Paccagnella A, Favaretto A, Oniga F, et al: Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43:83-91, 2004
14. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 19:3210-3218, 2001
15. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422, 1999
16. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1-12, 1996
17. Pfiste DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 22:330-353, 2004
18. Parmar MB, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834, 1998
19. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558, 2002
20. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
21. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
22. Egger M, Smith GD, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997
23. Bissett D, Nicolson M, Falk S, et al: Randomised phase 2 study of tirapazamine with either cisplatin or carboplatin in advanced NSCLC. Proc Am Soc Clin Oncol 20:346a, 2001 (abstr 1381)
24. Williamson SK, Crowley JJ, Lara PN, et al: S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Oncol 22:622, 2003 (abstr 2502)
25. Clarke MJ, Stewart LA: Obtaining individual patient data from randomized controlled trials, in Egger M, Smith GD, and Altman DG (eds): Systematic Reviews in Health Care. London, UK, BMJ Publishing Group, 2001, pp 109-121